Liraglutide

ATC CodeA08AX02, A10BJ02
CAS number204656-20-2
PUB number16134956
Drugbank IDDB06655
Empirical formulaC172H265N43O51
Physical statesolid

Basics

Liraglutide is a so-called incretin mimetic or GLP-1 analog. It is used to treat type 2 diabetes mellitus and to prevent cardiovascular complications associated with diabetes. In addition, it is approved for the treatment of obesity above a BMI of 30 in combination with dietary measures. It is administered as a subcutaneous injection.

Liraglutide was developed by Novo-Nordisk and was approved in the United States in 2010 and in the European Union in 2009.

Pharmacology

Pharmacodynamics

Liraglutide is a synthetically produced analog of the endogenous "glucagon-like-peptide-1" (GLP-1). The major advantage of this active ingredient lies in its modified structure, as it has a greatly extended retention time in the blood due to the addition of a fatty acid and a slight modification of the amino acid sequence. The endogenously occurring GLP-1, on the other hand, is broken down in the body by the body's own enzymes in the intestine after only about 1-2 minutes.

Like GLP-1, liraglutide binds to the glucagon-like peptide-1 receptor. Binding to the receptor and the resulting increase in cyclic AMP stimulates the glucose-dependent release of insulin, inhibits the glucose-dependent release of glucagon, and slows gastric emptying. Through these mechanisms, post-meal blood glucose levels are kept low.

Pharmacokinetics

The bioavailability of liraglutide after subcutaneous injection is approximately 55% and the maximum plasma concentration is reached after approximately 11 hours. Liraglutide is present in the blood more than 98% bound to serum albumin. Due to its altered structure, liraglutide is degraded and metabolized much more slowly by the enzyme dipeptidyl peptidase-4 (DPP4), which is why its plasma half-life is about 13 hours.

Toxicity

Side effects

  • Nausea
  • Emesis
  • Diarrhea
  • constipation
  • Headache

In rare cases, pancreatitis may occur. A slightly increased risk of developing medullary thyroid carcinoma is associated with its use.

Markus Falkenstätter, BSc

Markus Falkenstätter, BSc

Mag. pharm. Stefanie Lehenauer

Mag. pharm. Stefanie Lehenauer



Logo

Your personal medication assistant

Drugs

Browse our extensive database of medications from A-Z, including effects, side effects, and dosage.

Substances

All active ingredients with their effects, applications, and side effects, as well as the medications they are contained in.

Diseases

Symptoms, causes, and treatments for common diseases and injuries.

Social media

The presented content does not replace the original package insert of the medication, especially regarding the dosage and effects of individual products. We cannot assume liability for the accuracy of the data, as the data has been partially converted automatically. Always consult a doctor for diagnoses and other health-related questions.

© medikamio